Funds Support Further Development of V-Wave Implantable Interatrial Cardiac Shunt for Heart Failure and Pulmonary Hypertension CAESAREA, ISRAEL AND AGOURA HILLS, CALIFORNIA – V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive...
CE Mark for the Ventura™ Interatrial Shunt System is a significant milestone for V-Wave, as it recognizes that this therapeutic product conforms to the standards of the European Medical Device Directive V-Wave Ltd., a privately held medical device company developing...
CE Mark for the Ventura™ Interatrial Shunt System is a significant milestone for V-Wave, as it recognizes that this therapeutic product conforms to the standards of the European Medical Device Directive V-Wave Ltd., a privately held medical device company developing...
FDA Breakthrough Device Designation is granted to devices that have the potential to offer a “more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases.” V-Wave Ltd., a privately held medical device company developing novel...
Renowned heart failure cardiologist, Dr. William T. Abraham, makes this move to V-Wave after more than 16 years as Director of the Division of Cardiovascular Medicine at The Ohio State University. V-Wave Ltd., an early stage medtech company developing an implantable...
RELIEVE-HF is a global, randomized, controlled, double-blinded, 500 patient pivotal study to evaluate the safety and effectiveness of V-Wave’s novel therapy. V-Wave Ltd. announced today that it has enrolled the first patients in its global, 500 patient pivotal study...
Recent Comments